Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

What is required for consistent IHC & ISH staining and diagnostic confidence?

Immunohistochemistry (IHC), in situ hybridization (ISH) and other slide-based molecular tests are the more complex and clinically valuable tests performed in the histology laboratory. Advances in laboratory automation have made these technologies more accessible in the routine diagnostic workflow. However, staining quality and consistency is still variable within and between laboratories. Interestingly, the largest source of variability observed in an IHC stain is not due to the staining process, but due to the pre-staining processes as shown in Figure 1.

Standardization of fixation, grossing and tissue processing with advanced staining techniques are now widely recognized as critical in maintaining consistent, high quality stains. This is reflected in the 2013 ASCO/CAP guidelines for HER2 IHC testing in breast cancer, describing optimal conditions from fixation to staining. Standardization of these steps will only become more important with the growth of companion and molecular diagnostics as well as with the growth of ePathology all of which rely on consistency across the entire diagnostic process.

A vision for high-quality IHC and ISH.

At Leica Biosystems our vison is to advance cancer diagnostics and improve lives. One way we can achieve this vision is by helping improve staining quality. As we recognize that IHC and ISH quality doesn‘t begin at the stainer, this series looks at many different aspects of staining quality, and considers how future tests will influence improved diagnosis.

This reference document is presented as a service to health care professionals by Leica Biosystems and has been compiled from available literature. Although every effort has been made to report faithfully the information, Leica cannot be held responsible for the correctness. This document is not intended to be, and should not be construed as medical advice. For any use, the product information guides, inserts and operation manuals of the various drugs and devices should be consulted. Leica Biosystems and the editors disclaim any liability arising directly or indirectly from the use of drugs, devices, techniques or procedures described in this reference document.

Copyright © by Leica Biosystems Melbourne Pty Ltd, Melbourne, Australia, 2016. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH. 95.14104 Rev A ∙ 04/2016